The revolutionary BiVACOR heart device was moved to Phase 2 of FDA trials after success in five human patients.
A promising new mRNA-based vaccine for pancreatic cancer has shown potential in reducing the recurrence of the disease post-surgery. MSK's phase 1 cli ...